School of Physics, Mathematics, and Computing, Faculty of Engineering and Mathematical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
GenesisCare, Wembley, Western Australia, Australia.
J Appl Clin Med Phys. 2022 Nov;23(11):e13652. doi: 10.1002/acm2.13652. Epub 2022 May 15.
Matching multiple linacs to common baseline data allows patients to be treated, and patient-specific quality assurance (PSQA) to be completed on any linac. Stereotactic body radiotherapy (SBRT) requires higher levels of accuracy and quality assurance than routine radiotherapy. The achieved linac matching must therefore be evaluated before distributive treatment or PSQA models can be implemented safely. This investigation aimed to propose metrics for defining linacs to be matched for SBRT deliveries, assess 12 linacs against these criteria, and determine if a distributive PSQA model could be implemented by reviewing the rates of false PSQA results. Ten SBRT spine plans were delivered by 12 matched Elekta linacs and measured using one of seven SRS MapCHECK devices. For gamma criteria of (3%, 2 mm), 96.9% of equivalent location detectors, showed a range of gamma ≤ 1.0 and 99.9% showed a standard deviation of ≤ 0.5. For criteria of (3%,1 mm) and (2%,1 mm), these ranges decreased to 92.1% and 80.2% while the standard deviations decreased to 99.3% and 95.7%, respectively. The dose differences showed that 43.6%, 82.7%, and 91.4% of detectors had a dose range of ≤ 3.0%, ≤ 5.0%, and ≤ 6.0%, respectively. Standard deviations of dose differences were 1.5%, 2.5%, and 3.0% for 94.1%, 98.3%, and 99.5% of detectors, respectively. For the fleet of linacs, distributive PSQA yielded false results for 0.0%, 17.7%, and 33.0% of plans, equivalent to 1.2%, 3.5%, and 9.4% of detectors when using gamma criteria of (3%,2 mm), (3%,1 mm), or (2%,1 mm), respectively. These linacs could be considered matched for SBRT treatments and implement a distributive PSQA model when gamma analysis was completed with a criterion of (3%, 2 mm). For stricter criterion of (3%,1 mm) or (2%,1 mm), they did not meet the proposed metrics.
将多个直线加速器与共同的基准数据相匹配,可以在任何直线加速器上对患者进行治疗,并完成针对每个患者的质量保证(PSQA)。立体定向体放射治疗(SBRT)需要比常规放射治疗更高水平的准确性和质量保证。因此,在实施分布式治疗或 PSQA 模型之前,必须对所获得的直线加速器匹配进行评估。本研究旨在提出用于定义 SBRT 治疗所需匹配的直线加速器的指标,根据这些标准评估 12 台直线加速器,并通过检查虚假 PSQA 结果的比率来确定是否可以实施分布式 PSQA 模型。10 个 SBRT 脊柱计划由 12 台匹配的 Elekta 直线加速器交付,并使用七个 SRS MapCHECK 设备之一进行测量。对于伽马标准(3%,2 毫米),96.9%的等效位置探测器显示伽马值≤1.0,99.9%显示标准偏差≤0.5。对于(3%,1 毫米)和(2%,1 毫米)标准,这些范围分别减小到 92.1%和 80.2%,而标准偏差分别减小到 99.3%和 95.7%。剂量差异表明,43.6%,82.7%和 91.4%的探测器的剂量范围分别≤3.0%,≤5.0%和≤6.0%。对于 94.1%,98.3%和 99.5%的探测器,剂量差异的标准偏差分别为 1.5%,2.5%和 3.0%。对于该直线加速器机群,当使用伽马标准(3%,2 毫米),(3%,1 毫米)或(2%,1 毫米)时,分布式 PSQA 分别为 0.0%,17.7%和 33.0%的计划产生了错误结果,相当于当使用(3%,2 毫米)伽马标准时,探测器的 1.2%,3.5%和 9.4%。当使用伽马标准(3%,2 毫米)完成伽马分析时,这些直线加速器可以被认为适用于 SBRT 治疗,并可以实施分布式 PSQA 模型。对于更严格的(3%,1 毫米)或(2%,1 毫米)标准,它们不符合所提出的指标。